Seminars in Oncology
Volume 33, Issue 1 , Pages 106-120, February 2006

Gastrointestinal Toxicity of Chemotherapeutic Agents

  • Edith P. Mitchell

      Affiliations

    • Corresponding Author InformationAddress correspondence to Edith P. Mitchell, MD, Division of Medical Oncology, Thomas Jefferson University, 125 S Ninth St, Sheridan Building, Suite 801, Philadelphia, PA 19107

Division of Medical Oncology, Thomas Jefferson University, Philadelphia, PA

Chemotherapy-induced toxicities commonly occur in sites within the gastrointestinal (GI) tract and account for dose-limiting effects. These toxicities are major contributing factors to dose reduction, delays, and cessation of cancer treatment. Through intensive therapies including surgery, combination chemotherapy, hormonal therapy, and targeted therapy, an increasing number of patients with cancer are experiencing improved survival and long-term disease-free survival, as well as palliation of disease-related symptoms. Thus, GI toxicities should be predicted and appropriate interventions initiated to prevent them when possible and provide effective supportive measures and comprehensive follow-up care. This review will discuss the etiology, incidence, prevention, and treatment of GI toxicities of cancer chemotherapy.

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.
 

PII: S0093-7754(05)00494-X

doi:10.1053/j.seminoncol.2005.12.001

Seminars in Oncology
Volume 33, Issue 1 , Pages 106-120, February 2006